Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
The six-part webinar series aims to enhance awareness, diagnosis, and management of autoimmune diseases
The approval was driven by data from the Phase III TULIP-SC trial
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
